Developer docs
API playgroundTry for free, no card

Search company profiles

Stimuliver

Full company profile

uuid000ah4n

Namestring
Stimuliver
Legal namestring
Stimuliver ApS
Websiteurl
stimuliver.bio
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Stimuliver is a pre-clinical biotechnology company developing a first-in-class, vascularized, and immunomodulatory 3D liver tissue implant intended to treat acute and chronic liver disease. Founded by University of Edinburgh researchers David Hay (CEO) and Dagmara Szkolnicka (CSO), the company is a spinout from Edinburgh Innovations and is incubated at the BioInnovation Institute (BII) in Copenhagen, Denmark. Its core technology differentiates human pluripotent stem cells into hepatic progenitors and endothelial cells, combines them into spheres, and scales the tissue through an automated platform for subcutaneous implantation that bypasses the inflamed abdomen characteristic of liver patients.

The lead product is a subcutaneous liver tissue implant positioned as an off-the-shelf, renewable regenerative therapy that does not depend on donor organ availability. The platform has demonstrated vascularization to the host system within days of implantation and long-term host liver support in rodent models. Stimuliver also produces 3D liver spheroids as a research-grade product for basic and applied research. Four patent applications have been filed by the founding team in the area of stem cell differentiation toward liver tissue.

Stimuliver is pre-revenue and pre-commercial; the planned revenue model is one-time product licensing/sales to healthcare providers and transplant centers following regulatory approval. The company is financed by BioInnovation Institute (EUR 500k convertible loan), Vaekstfonden (DKK 15m co-investor in the 2022 seed), Old College Capital (undisclosed 2023 round), and Innovation Fund Denmark (DKK 2.4m Innobooster grant in 2023). A Scientific Advisory Board drawn from King's College London, MIT, the University of Edinburgh, and Verigraft provides translational and clinical guidance.

Short descriptiontext

Stimuliver is a pre-clinical biotech developing a first-in-class subcutaneous 3D liver tissue implant using pluripotent stem cells, offering an off-the-shelf regenerative alternative to donor-organ transplants for acute and chronic liver disease patients.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersCopenhagen, Denmark
HQ citystring
Copenhagen
HQ countrystring
Denmark
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
regenerative medicine, liver tissue implants, stem cell therapy, tissue engineering, biotech therapeutics
Industry1 code
PRIMARYHLAAAGAB
Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Biological Products, (No Disgnostic Substances)2836
Product category
Regenerative Medicine
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Liver Tissue Implant Commercialization
TypeOne Time License
Description

Pre-revenue stage. The company is developing an off-the-shelf regenerative medicine product—a liver tissue implant for treating acute and chronic liver diseases. Revenue will be generated through product sales to healthcare providers once regulatory approval is obtained.

stimuliver.bio
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Cost components3 values
Personnel, Technology or R&D, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Stimuliver is a pre-clinical biotechnology company developing a vascularized and immunomodulatory liver tissue implant from human pluripotent stem cells. The implant uses hepatic progenitors and endothelial cells combined into spheres, produced through an automated platform, and delivered subcutaneously to filter toxins and supplement failing liver function as an off-the-shelf regenerative treatment for acute and chronic liver diseases.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Vascularization to host system within few days
+1 more record
Product overview1 text field

Stimuliver is a regenerative medicine company developing a single integrated product portfolio centered on its liver tissue implant technology. The core offering is a first-in-class vascularized and immunomodulatory liver tissue implant that uses pluripotent stem cells differentiated into liver tissue, delivered via a subcutaneous remote implant. The technology consists of three interconnected components: the liver tissue implant (core therapeutic product), the remote implant technology (delivery mechanism), and 3D liver spheroids (research-grade product). All offerings are built on the same platform technology of differentiating pluripotent stem cells into viable liver tissue for scalable, off-the-shelf treatment of liver diseases.

Product and service2 records
1Liver Tissue Implant
CategoryCell-based therapeutics
Description

A first-in-class vascularized and immunomodulatory liver tissue implant for treating acute and chronic liver diseases. Human pluripotent stem cells are differentiated into hepatic progenitors and endothelial cells, combined into spheres, scaled through an automated platform, and implanted subcutaneously to filter toxins and support failing liver function. Designed for healthcare providers managing severe liver disease patients.

23D Liver Spheroids
CategoryResearch products
Description

Human liver spheroids produced through an automated platform from pluripotent stem cells for use in basic and applied liver research. Targeted at researchers and pharma applications requiring cost-effective human liver tissue models.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-05-28
Description

Stimuliver is a spinout from Edinburgh Innovations, the University of Edinburgh's commercialisation service. The company's technology originates from world-leading research at the University of Edinburgh in liver tissue engineering.

2Scientific Advisory Board Members
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-01-01
Description

Stimuliver's Scientific Advisory Board includes Prof. Fiona Watt (King's College London), Prof. Linda Griffith (MIT), Prof. Giovanna Lombardi (King's College London), Dr. Petter Björquist (Verigraft), Prof. Jonathan Fallowfield (University of Edinburgh), and Mr. Ian Currie (University of Edinburgh). The board guides development of the liver implant technology.

stimuliver.bio
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Pioneer in 3D bioprinted human tissues including liver tissue for therapeutic and research applications; later pivoted to drug discovery. Comparable 3D liver tissue engineering focus.

2Aspect Biosystems
TypeEmerging player
Description

Develops bioprinted tissue therapeutics using stem-cell-derived cells and microfluidic 3D bioprinting. Comparable platform approach combining automation, stem cells, and tissue engineering.

TypeRegional player
Description

Commercializes extracorporeal blood-purification devices used as supportive care in liver failure and critical illness. Comparable liver-failure therapeutic category though non-cell-based modality.

TypeEmerging player
Description

Develops a tissue-engineering platform that grows ectopic organs (including livers) inside lymph nodes using patient hepatocytes — alternative regenerative medicine approach for liver failure directly comparable to Stimuliver's off-the-shelf liver tissue strategy.

TypeEmerging player
Description

Develops engineered xenotransplant organs including genetically-modified pig livers for patients with liver failure. Competes with Stimuliver as an alternative donor-independent liver replacement strategy.

TypeBroad incumbent
Description

Commercial-stage tissue engineering company using human cells to grow bioengineered vessels and tissues at scale. Most direct publicly-traded peer in tissue-engineered regenerative medicine.

7Sigilon Therapeutics
TypeEmerging player
Description

Develops cell-encapsulation therapies for chronic diseases using engineered cells. Comparable cell-based therapeutic platform targeting organ-level dysfunction.

TypeEmerging player
Description

Developed cell-based therapies for liver disease, including hepatic progenitor cell infusions for ACLF and pediatric metabolic disorders. Comparable regenerative medicine approach to liver failure.

9Vertex Pharmaceuticals (VX-880 program)
TypeBroad incumbent
Description

Vertex's VX-880 is a stem-cell-derived islet cell therapy for type 1 diabetes — analogous cell-therapy modality (encapsulated stem-cell-derived cells) reaching clinical proof-of-concept, useful benchmark for Stimuliver's regulatory and manufacturing trajectory.

TypeBroad incumbent
Description

Acquired by United Therapeutics, Miromatrix developed bioengineered organs and tissues including liver constructs using decellularized scaffolds — directly comparable to Stimuliver's tissue-engineered liver approach but at a much later stage with corporate backing.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Stimuliver

Regenerative Medicinestimuliver.bio

Stimuliver is a pre-clinical biotech developing a first-in-class subcutaneous 3D liver tissue implant using pluripotent stem cells, offering an off-the-shelf regenerative alternative to donor-organ transplants for acute and chronic liver disease patients.

What Stimuliver does

Stimuliver is a pre-clinical biotechnology company developing a first-in-class, vascularized, and immunomodulatory 3D liver tissue implant intended to treat acute and chronic liver disease. Founded by University of Edinburgh researchers David Hay (CEO) and Dagmara Szkolnicka (CSO), the company is a spinout from Edinburgh Innovations and is incubated at the BioInnovation Institute (BII) in Copenhagen, Denmark. Its core technology differentiates human pluripotent stem cells into hepatic progenitors and endothelial cells, combines them into spheres, and scales the tissue through an automated platform for subcutaneous implantation that bypasses the inflamed abdomen characteristic of liver patients.

The lead product is a subcutaneous liver tissue implant positioned as an off-the-shelf, renewable regenerative therapy that does not depend on donor organ availability. The platform has demonstrated vascularization to the host system within days of implantation and long-term host liver support in rodent models. Stimuliver also produces 3D liver spheroids as a research-grade product for basic and applied research. Four patent applications have been filed by the founding team in the area of stem cell differentiation toward liver tissue.

Stimuliver is pre-revenue and pre-commercial; the planned revenue model is one-time product licensing/sales to healthcare providers and transplant centers following regulatory approval. The company is financed by BioInnovation Institute (EUR 500k convertible loan), Vaekstfonden (DKK 15m co-investor in the 2022 seed), Old College Capital (undisclosed 2023 round), and Innovation Fund Denmark (DKK 2.4m Innobooster grant in 2023). A Scientific Advisory Board drawn from King's College London, MIT, the University of Edinburgh, and Verigraft provides translational and clinical guidance.

Stimuliver firmographics

Firmographics
Name
Stimuliver
Legal name
Stimuliver ApS
Website
https://stimuliver.bio
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
1–10 employees
Short description
Stimuliver is a pre-clinical biotech developing a first-in-class subcutaneous 3D liver tissue implant using pluripotent stem cells, offering an off-the-shelf regenerative alternative to donor-organ transplants for acute and chronic liver disease patients.
Ownership category
akta.pro rank

Stimuliver industry classification

Industry
Product category
Regenerative Medicine
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Surgical & Medical Instruments & Apparatus (3841), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAGAB
Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

Keywords

  • Regenerative medicine
  • Liver tissue implants
  • Stem cell therapy
  • Tissue engineering
  • Biotech therapeutics

Where Stimuliver is headquartered

Location

Headquarters

HQ city
Copenhagen
HQ country
Denmark
HQ region
Europe

Offices1 record

Markets served

Stimuliver business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations

Revenue model

  1. Liver Tissue Implant Commercialization: Pre-revenue stage. The company is developing an off-the-shelf regenerative medicine product—a liver tissue implant for treating acute and chronic liver diseases. Revenue will be generated through product sales to healthcare providers once regulatory approval is obtained.

Go-to-market motion1 record

Marketing channels4 records

Stimuliver product offering

Product offering

Core offering

Stimuliver is a pre-clinical biotechnology company developing a vascularized and immunomodulatory liver tissue implant from human pluripotent stem cells. The implant uses hepatic progenitors and endothelial cells combined into spheres, produced through an automated platform, and delivered subcutaneously to filter toxins and supplement failing liver function as an off-the-shelf regenerative treatment for acute and chronic liver diseases.

Product overview

Stimuliver is a regenerative medicine company developing a single integrated product portfolio centered on its liver tissue implant technology. The core offering is a first-in-class vascularized and immunomodulatory liver tissue implant that uses pluripotent stem cells differentiated into liver tissue, delivered via a subcutaneous remote implant. The technology consists of three interconnected components: the liver tissue implant (core therapeutic product), the remote implant technology (delivery mechanism), and 3D liver spheroids (research-grade product). All offerings are built on the same platform technology of differentiating pluripotent stem cells into viable liver tissue for scalable, off-the-shelf treatment of liver diseases.

Differentiator

Problem solved

Functional benefit

Products and services

  • Liver Tissue Implant A first-in-class vascularized and immunomodulatory liver tissue implant for treating acute and chronic liver diseases. Human pluripotent stem cells are differentiated into hepatic progenitors and endothelial cells, combined into spheres, scaled through an automated platform, and implanted subcutaneously to filter toxins and support failing liver function. Designed for healthcare providers managing severe liver disease patients.
  • 3D Liver Spheroids Human liver spheroids produced through an automated platform from pluripotent stem cells for use in basic and applied liver research. Targeted at researchers and pharma applications requiring cost-effective human liver tissue models.

Quantifiable outcome

  • Vascularization to host system within few days
  • +1 more outcomes

Companies that use Stimuliver

Customer profile

Segments1 record

Ideal customer profiles1 record

Stimuliver technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Stimuliver partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Edinburgh Innovations (University of Edinburgh)coreStrategic or Co-development Partner · 28 May 2022Stimuliver is a spinout from Edinburgh Innovations, the University of Edinburgh's commercialisation service. The company's technology originates from world-leading research at the University of Edinburgh in liver tissue engineering.
  • Scientific Advisory Board MemberscoreStrategic or Co-development Partner · 1 January 2019Stimuliver's Scientific Advisory Board includes Prof. Fiona Watt (King's College London), Prof. Linda Griffith (MIT), Prof. Giovanna Lombardi (King's College London), Dr. Petter Björquist (Verigraft), Prof. Jonathan Fallowfield (University of Edinburgh), and Mr. Ian Currie (University of Edinburgh). The board guides development of the liver implant technology.

Scale indicators5 records

Recent moves5 records

Expansion highlights4 records

Stimuliver competitors and assessment

Company assessment

Emerging players

  • Organovo: Pioneer in 3D bioprinted human tissues including liver tissue for therapeutic and research applications; later pivoted to drug discovery. Comparable 3D liver tissue engineering focus.
  • Aspect Biosystems: Develops bioprinted tissue therapeutics using stem-cell-derived cells and microfluidic 3D bioprinting. Comparable platform approach combining automation, stem cells, and tissue engineering.
  • LyGenesis: Develops a tissue-engineering platform that grows ectopic organs (including livers) inside lymph nodes using patient hepatocytes — alternative regenerative medicine approach for liver failure directly comparable to Stimuliver's off-the-shelf liver tissue strategy.
  • eGenesis: Develops engineered xenotransplant organs including genetically-modified pig livers for patients with liver failure. Competes with Stimuliver as an alternative donor-independent liver replacement strategy.
  • Sigilon Therapeutics: Develops cell-encapsulation therapies for chronic diseases using engineered cells. Comparable cell-based therapeutic platform targeting organ-level dysfunction.
  • Promethera Biosciences (now Cytonet): Developed cell-based therapies for liver disease, including hepatic progenitor cell infusions for ACLF and pediatric metabolic disorders. Comparable regenerative medicine approach to liver failure.

Regional players

  • CytoSorbents: Commercializes extracorporeal blood-purification devices used as supportive care in liver failure and critical illness. Comparable liver-failure therapeutic category though non-cell-based modality.

Broad incumbents

  • Humacyte: Commercial-stage tissue engineering company using human cells to grow bioengineered vessels and tissues at scale. Most direct publicly-traded peer in tissue-engineered regenerative medicine.
  • Vertex Pharmaceuticals (VX-880 program): Vertex's VX-880 is a stem-cell-derived islet cell therapy for type 1 diabetes — analogous cell-therapy modality (encapsulated stem-cell-derived cells) reaching clinical proof-of-concept, useful benchmark for Stimuliver's regulatory and manufacturing trajectory.
  • Miromatrix Medical (United Therapeutics): Acquired by United Therapeutics, Miromatrix developed bioengineered organs and tissues including liver constructs using decellularized scaffolds — directly comparable to Stimuliver's tissue-engineered liver approach but at a much later stage with corporate backing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights7 records

Customer concentration

Stimuliver social profiles

Digital presence

Stimuliver financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Stimuliver leadership team

Management profile

Number of profiles

Profiles15 records

Stimuliver funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Stimuliver M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Stimuliver

What does Stimuliver do?

Stimuliver is a pre-clinical biotechnology company developing a vascularized and immunomodulatory liver tissue implant from human pluripotent stem cells. The implant uses hepatic progenitors and endothelial cells combined into spheres, produced through an automated platform, and delivered subcutaneously to filter toxins and supplement failing liver function as an off-the-shelf regenerative treatment for acute and chronic liver diseases.

Is Stimuliver a public or private company?

Stimuliver is a private company. It is classified as venture growth investor backed and is currently operating.

When was Stimuliver founded?

Stimuliver was founded in 2019. It employs 1 to 10 people.

Where is Stimuliver based?

Stimuliver is headquartered in Copenhagen, Denmark, in the Europe region.

How does Stimuliver make money?

One revenue line is on record: liver Tissue Implant Commercialization.

Who are Stimuliver's main competitors?

Emerging players on record are Organovo, Aspect Biosystems, LyGenesis, eGenesis, Sigilon Therapeutics and Promethera Biosciences (now Cytonet). CytoSorbents is listed as a regional player. Broad incumbents are Humacyte, Vertex Pharmaceuticals (VX-880 program) and Miromatrix Medical (United Therapeutics).

Does Stimuliver have an API?

No public API is recorded for Stimuliver.

What industry is Stimuliver in?

Stimuliver's product category is Regenerative Medicine. Its primary akta.pro industry code is HLAAAGAB, Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials). Its NAICS code is 325414 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales